NASDAQ NMS - GLOBAL MARKET · GILD

-2.14% · -$3.18 · Vol 3.9M

Market closed · last close 4:00 PM ET · price as of 16:54:04 ET

Gilead Sciences, Inc

Biotechnology

$145.68

Card

Relationship Map

Veridion Score

BETALOW CONF · 6/6 factors

Fri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET · GILD

Methodology

GILD

Gilead Sciences, Inc

Fri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET

51/100

NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

51/ 100

Veridion Score

NEUTRAL · LOW confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: LOW · 6/6 factors with data · Fri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is GILD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move GILD next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Form 4

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 27
Form 4Checking access
WELTERS ANTHONY Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 21
Form 4Checking access
Bluestone Jeffrey Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 18
Form 4Checking access
Mercier Johanna Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 18
Form 4Checking access
Dickinson Andrew D Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 4
Form 4Checking access
O'Day Daniel Patrick Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Jul 20
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jul 16
Form 4Checking access
Dickinson Andrew D Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Jul 16
Form 4Checking access
Mercier Johanna Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Jul 7
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jul 2
Form 4Checking access
O'Day Daniel Patrick Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access

About Gilead Sciences, Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

1992

Employees

17K

Country

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$149.47

Day high

$149.47

Day low

$144.88

Previous close

$148.86

52W high

$155.80

-6.50% from high

52W low

$110.56

78% of range

Market cap

$180.6B

P/E

19.96×

EPS

$-2.8500

Beta

0.11

Shares out

1.2B

Volume

3.9M

0.63× rel vol

Avg volume

6.3M

VWAP

$145.93

Price history computed in-house

-0.30%

+11.88%

+11.12%

+28.95%

YTD

+18.69%

SMA 50 $134.10 · above

SMA 200 $133.72 · above

52W position 78%

GILD overview

Veridion Score

Registered · 2026-08-28

6 of 6 factors measured

Relationship mapTrace receipt-backed holders and filings around GILD.Congress disclosuresOpen receipt and filing context for GILD.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

GILD insider activity

Gilead Sciences, Inc

Score

51 · NEUTRAL

Pressure

Net selling

Filings

Buys / sells

0 / 26

Net value

-$15.0M

Insiders

Named filers

WELTERS ANTHONY

Director

Board

Bluestone Jeffrey

Director

Board

Mercier Johanna

Chief Comm & Corp Aff Officer

C-Suite

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$15.0M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Scroll across filed transactions. Filing date stays visible.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-08-27	2026-08-26	WELTERS ANTHONY	Director	sell	$148.82	6,880	12,894	$1.0M	SEC Form 4
2026-08-27	2026-08-26	WELTERS ANTHONY	Director	sell	$148.82	4,600	12,894	$685K	SEC Form 4
2026-08-27	2026-08-26	WELTERS ANTHONY	Director	sell	$148.24	3,402	19,774	$504K	SEC Form 4